Imaging beyond the diagnosis: Image-guided enzyme/prodrug cancer therapy

Acta Biochimica et Biophysica Sinica

Volumn 43, Issue 1, 2011, Pages 4-12

  Tong, Xinyi ^a   Chen, Xishan ^a   Li, Cong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

cancer; enzyme; molecular imaging; prodrug; therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSINE DEAMINASE; ENZYME; PRODRUG; THYMIDINE KINASE;

ANIMAL; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSINE DEAMINASE; ENZYMES; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRODRUGS; THYMIDINE KINASE;

EID: 78650740921     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq113     Document Type: Review

References (43)

1. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP and Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006, 98: 1108-1117.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5: 219-234.
3. Xu G and McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 2001, 7: 3314-3324.
4. Niculescu-Duvaz I and Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005, 30: 71-88.
5. Schepelmann S and Springer CJ. Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 2006, 6: 647-670.
6. Springer CJ and Niculescu-Duvaz I. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv Drug Deliv Rev 1997, 26: 151-172.
7. Bagshawe KD, Sharma SK, Burke PJ, Melton RG and Knox RJ. Developments with targeted enzymes in cancer therapy. Curr Opin Immunol 1999, 11: 579-583.
8. Li C, Winnard P, Jr, Takagi T, Artemov D and Bhujwalla ZM. Multimodal image-guided enzyme/prodrug cancer therapy. J Am Chem Soc 2006, 128: 15072-15073.
9. Li C, Penet MF, Winnard P, Jr, Artemov D and Bhujwalla ZM. Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res 2008, 14: 515-522.
10. Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U and Tolner B, et al. Chester sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody directed enzyme prodrug therapy. Clin Cancer Res 2005, 11: 814-825.
11. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996, 271: 1079-1080.
12. Yazawa K, Fisher WE and Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg 2002, 26: 783-789.
13. Greco O and Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001, 187: 22-36.
14. Koo V, Hamilton PW and Williamson K. Non-invasive in vivo imaging in small animal research. Cell Oncol 2006, 28: 127-139.
15. Aime S, Botta M, Fasano M and Terreno E. Lanthanide(III) chelates for NMR biomedical applications. Chem Soc Rev 1998, 27: 19-29. (Pubitemid 128653038)
16. Wagenaar DJ, Kapusta M, Li J and Patt BE. Rationale for the combination of nuclear medicine with magnetic resonance for pre-clinical imaging. Technol Cancer Res Treat 2006, 5: 343-350.
17. Achilefu S. Lighting up tumors with receptor-specific optical molecular probes. Technol Cancer Res Treat 2004, 3: 393-409.
18. Mulder WJ, Strijkers GJ, van Tilborg GA, Cormode DP, Fayad ZA and Nicolay K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res 2009, 42: 904-914.
19. Cheon J and Lee JH. Synergistically integrated nanoparticles as multimo-dal probes for nanobiotechnology. Acc Chem Res 2008, 41: 1630-1640.
20. Nam T, Park S, Lee SY, Park K, Choi K, Song IC and Han MH, et al. Tumor targeting chitosam nanoparticles for dual-modality molecular imaging. Bioconjug Chem 2010, 21: 578-582.
21. Tu C, Nagao R and Louie AY. Multimodal magnetic-resonance/ optical-imaging contrast agent sensitive to NADH. Angew Chem Int Ed Engl 2009, 48: 6547-6551.
22. Kim JS, An H, Rieter WJ, Esserman D, Taylor-Pashow KM, Sartor RB and Lin W, et al. Multimodal optical and Gd-based nanoparticles for imaging in inflammatory arthritis. Clin Exp Rheumatol 2009, 27: 580-586.
23. Seo WS, Lee JH, Sun X, Suzuki Y, Mann D, Liu Z and Terashima M, et al. FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents. Nat Mater 2006, 5: 971-976.
24. Aboagye EO, Artemov D, Senter PD and Bhujwalla ZM. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res 1998, 58: 4075-4078.
25. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y and Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004, 277: 39-61.
26. McCormick F. Cancer gene therapy: fringe or cutting edge. Nat Rev Cancer 2001, 1: 130-141.
27. Shah K, Jacobs A, Breakefield XO and Weissleder R. Molecular imaging of gene therapy for cancer. Gene Ther 2004, 11: 1175-1187.
28. Weissleder R and Pittet MJ. Imaging in the era of molecular oncology. Nature 2008, 452: 580-589.
29. Wang HE, Yu HM, Liu RS, Lin M, Gelovani JG, Hwang JJ and Wei HJ, et al. Molecular imaging with 123I-FIAU, 18F-FudR, 18F-FET and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activating gene therapy of cancer. J Nucl Med 2006, 47: 1161-1171.
30. 18F]FEAU PET. PLoS One 2009, 4: e4789.
31. MacLaren DC, Gambhir SS, Satyamurthy N, Barrio JR, Sharfstein S, Toyokuni T and Wu L, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999, 6: 785-791. (Pubitemid 29243651)
32. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR and Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide sym-porter as reporter gene. Hum Gene Ther 2002, 13: 1723-1735.
33. Jung KH, Paik JY, Ko BH and Lee KH. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells. J Nucl Med 2008, 49: 1966-1972.
34. Altaner C. Prodrug cancer gene therapy. Cancer Lett 2008, 270: 191-201.
35. Yaghoubi SS and Gambhir SS. Measuring herpes simplex virus thymidine kinase reporter gene expression in vitro. Nat Protoc 2006, 1: 2137-2142.
36. Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR and Iyer M, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 2000, 97: 2785-2790.
37. Black ME, Kokoris MS and Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001, 61: 3022-3026.
38. 18F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thy-midine kinase reporter gene expression. J Nucl Med 2001, 42: 1225-1234.
39. 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk's expression. J Nucl Med 2006, 47: 706-715.
40. Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y and Rueckriem B, et al. Imaging-guided gene therapy of experimental gliomas. Cancer Res 2007, 67: 1706-1715.
41. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY and Cheson BD, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005, 11: 2785-2808.
42. 18F-fluorothymidine. J Nucl Med 2009, 50: 1441-1447.
43. Lindholm P, Lapela M, Nagren K, Lehikoinen P, Minn H and Jyrkkiö S. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 2009, 30: 30-36.